Chronic hepatitis B virus (HBV) infection remains a major global health burden. Currently, the approved therapeutic regimens include nucleos(t)ide analogues (NAs) and either interferon or pegylated interferon. NA therapy is generally safe and well tolerated, but the rate of posttreatment virologic relapse is high, making NA treatment a lifetime commitment. The benefits of pegylated interferon treatment include a finite duration, more-durable response and absence of viral resistance. However, sustained response to interferon alone is achieved only in a minority of patients, and side effects are common, which limit its clinical use. Given that HBV covalently closed circular DNA and the integrated HBV genome persist stably in the nuclei of infected hepatocytes, elimination (complete cure) of HBV is rarely achieved. After completion of treatment, sustained HBV surface antigen loss, with or without seroconversion to HBV surface antibody positivity (ie, functional cure), is therefore recommended as the ideal end point for anti-HBV treatment, despite the lack of complete eradication of HBV. Theoretically, combination of antiviral agents with differential mechanisms of actions on HBV, including viral suppression combined with immune modulation (as occurs during treatment with NA plus pegylated interferon), is an encouraging strategy to treat chronic hepatitis B. Recent studies have confirmed certain virological and serological advantages of simultaneous administration of NA and pegylated interferon (de novo combination therapy) or addition of pegylated interferon to ongoing NA therapy (sequential combination therapy) over monotherapy. Few data exist, however, on the long-term outcomes of patients receiving combination therapy. This review summarizes current combination therapy developed to cure chronic HBV infection.
Hepatitis B virus (HBV) infection remains to be a major public health burden, approximately 240 million people worldwide are chronically infected with HBV, which contributes to about 30% of cirrhosis and 45% of hepatocellular carcinoma (HCC) cases [1, 2] . Both viral and host factors play important roles in the establishment and maintenance of persistent HBV infection. The HBV genome forms a stable minichromosome-covalently closed circular DNA (cccDNA)-within the nuclei of hepatocytes or integrates into the host genome, thereby enabling the infection to persist [3] . In addition, HBV is capable of suppressing the antiviral immune responses [4, 5] , and persistent exposure to high HBV loads and protein concentrations may cause impairment or exhaustion of T-cell functions, leading to immune escape [6, 7] .
The goal of anti-HBV therapy is to prevent the progression of disease to cirrhosis, end-stage liver disease, and hepatocellular carcinoma (HCC) and to improve the survival of patients with chronic hepatitis B, which can be attained initially through sustained immunological control of HBV infection and finally by complete elimination of HBV [8] [9] [10] . However, given that intrahepatic cccDNA, as well as the integrated HBV genome, persist stably even after the loss of HBV surface antigen (HBsAg), complete cure of HBV infection-defined as the true eradication of HBV DNA, including cccDNA-is rarely obtained. Serum HBsAg is considered a surrogate marker for cccDNA, and HBsAg seroclearance is known to be associated with functional remission and improved long-term outcome in patients with chronic hepatitis B. Although the HBV genome may not be eliminated and may persist at a very low level in such patients, the host immune system will mount an effective antiviral response against the few infected hepatocytes [11] [12] [13] . Therefore, functional cure-defined as HBsAg loss without true eradication of cccDNA-is recommended as the ideal end point of therapy and represents persistent suppression of viremia with sustained immune control of HBV infection [8] [9] [10] . This ideal end point may be attained with currently available antiviral agents in certain populations who receive appropriate baseline and response-guided therapy.
ADVANTAGES AND DISADVANTAGES OF CURRENT ANTI-HBV THERAPIES
Currently the approved therapeutic regimens include the uses of 2 classes of antiviral agents: nucleos(t)ide analogues (NAs), such as lamivudine (LAM), telbivudine (LdT), adefovir dipivoxil (ADV), entecavir (ETV), tenofovir disoproxil fumarate (TDF), and tenofovir alafenamide (TAF), which directly target the reverse transcription functions of polymerase and thus suppress HBV replication effectively [8, 14, 15] ; and interferon alfa (hereafter, "interferon") or its pegylated form, which have been shown to exert dual actions, including an immunomodulatory effect and modest direct antiviral activity against HBV [8, [14] [15] [16] [17] .
Successful antiviral therapy will suppress HBV replication in a sustained manner, with histological remission and a decreased risk of developing cirrhosis and HCC, especially among noncirrhotic patients. However, both NAs and interferon reduce but do not eliminate the risk of HCC, particularly in patients with preexisting cirrhosis [18] , and there is persistent risk for HCC even after suppression of HBV for more than a decade [19] . Both NAs and pegylated interferon have advantages and disadvantages. Because NA therapy is convenient to use and well tolerated and has potent antiviral activity, it has been widely used in the treatment of chronic hepatitis B. Although a recent study demonstrated a marked reduction in the cccDNA level after long-term NA treatment [20] , even the preferred NAs, ETV and TDF, do not directly suppress the transcriptional activity of cccDNA and have only mild effects on the production of viral antigens [21, 22] ; thus, sustained immune control is rarely achieved. Hepatitis B relapse or exacerbation after cessation of NA therapy is common, requiring NA treatment to be a lifetime commitment, particularly in HBV e antigen (HBeAg)-negative patients. Consequently, the lifetime need for NA therapy may increase the risks of poor adherence, HBV drug resistance (during long-term use of NAs with low genetic barriers to resistance, such as LAM, ADV, and LdT), and subsequent viral breakthrough and treatment failure. Unlike NAs, interferon exerts synergic effects, including promoting the activity of immune cells and the expression of cytokines and inducing the production of interferon-stimulated genes (ISGs), which encode antiviral proteins through a complex network of intracellular signaling pathways [16, 17] . Furthermore, several studies have shown that interferon can inhibit HBV transcription and reduce the production of viral antigen by enhancing degradation of HBV pregenomic RNA and core particles or by modifying epigenetic regulation of cccDNA [23, 24] . The benefits of interferon treatment include finite duration, marked reduction in serum HBsAg titer and more-durable response as compare, and absence of viral resistance. However, sustained response to interferon alone is achieved only in a minority of patients, such as younger patients, individuals with higher alanine aminotransferase levels, and those with a lower baseline HBV DNA level and HBsAg titer. In addition, side effects of interferon are common, which limits its clinical use [25, 26] .
Although sustained absence of HBsAg is the ideal end point for treatment of chronic hepatitis B, the frequency of HBsAg loss is low in patients receiving long-term NA or 1 year of pegylated interferon therapy (Table 1 ) [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] [43] . Therefore, novel therapeutic concepts, such as combination of available antiviral agents with differential mechanisms of actions on HBV (eg, NA plus pegylated interferon) is an encouraging strategy to achieve higher rates of HBsAg loss and, ideally, HBV surface antibody seroconversion.
INTERFERON-BASED COMBINATION THERAPY
Combination of NAs and pegylated interferon with differential antiviral actions may increase the likelihood of serologic response and sustained response after treatment cessation, thereby facilitating discontinuation of NA therapy, through TDF (8 y) 1.1 [37] Abbreviations: ADV, adefovir dipivoxil; ETV, entecavir; LAM, lamivudine; LdT, telbivudine; TDF, tenofovir disoproxil fumarate.
harnessing both direct antiviral and immunomodulatory mechanisms [44, 45] . The 2015 updated Asian-Pacific guidelines for the treatment of HBV infection address that combination treatment with NAs and pegylated interferon could be considered the ideal treatment for chronic hepatitis B [14] . The updated Chinese guidelines suggest that, in patients who achieved virological response due to long-term NA treatment, the addition of or switch to pegylated interferon is an alternative strategy to achieve a higher rate of HBeAg seroconversion and greater HBsAg decline than continuous NA monotherapy [43] . However, NA and interferon combination therapy is not recommended by either American guidelines or European guidelines [8, 15] .
DE NOVO COMBINATION THERAPY WITH PEGYLATED INTERFERON AND NA
Previous studies evaluating pegylated interferon in combination with LAM or ADV started simultaneously demonstrated that de novo combination therapy contributed to higher rates of virological response during treatment but failed to improve rates of sustained response after treatment [27, 38, 46, 47] . One study showed that ADV plus pegylated interferon combination therapy led to significant reductions in viral load, serum HBsAg titer, and intrahepatic HBV cccDNA level [28] . A multicenter randomized study investigated the efficacy of LdT and pegylated interferon combination therapy in HBeAg-positive patients with chronic hepatitis B and demonstrated that, despite leading to greater declines of viral load and serum HBsAg titer, combination therapy had an increased risk of unanticipated severe peripheral neuropathy and thereby should not be used [48] . A recent prospective randomized controlled trial evaluated HBsAg seroclearance in patients receiving monotreatment with TDF or pegylated interferon or combination treatment with TDF and pegylated interferon for 16 weeks or 48 weeks. This study showed that, 24 weeks after treatment, 48 weeks of TDF plus pegylated interferon combination therapy resulted in increased rates of HBsAg loss than either therapy given alone. However, the overall HBsAg loss rate remained low, with the highest rate occurring in patients infected with genotype A [49] . Furthermore, it is worth noting that an extended follow-up of these patients is essential to assess the long-term benefits and sustained responses after treatment cessation. Several studies have shown that host genetic background contributes to HBsAg loss induced by combination therapy [50] [51] [52] . A recent genome-wide association study identified that 1 single-nucleotide polymorphism (SNP) in the SLC16A9 gene, rs12356193, was strongly associated with HBsAg seroclearance among patients receiving combination therapy with ADV and pegylated interferon [50] . A randomized trial demonstrated that, in treatment-naive HBeAg-negative patients, combination therapy with ETV and pegylated interferon resulted in higher rates of undetectable viremia at week 48 but failed to increase HBsAg decline and clearance, compared with pegylated interferon monotherapy. Intriguingly, rs3077 GG genotype carriers with a baseline HBsAg level of <1000IU/mL had a good chance of attaining virological response and HBsAg loss, indicating that the host genetic characteristics may help individualize treatment decisions before combination therapy is initiated [52] . Although simultaneous administration of NAs other than TDF plus pegylated interferon may not lead to durable response, the optimal combination therapy for the treatment of chronic hepatitis B remains to be determined and should be taken into consideration, along with the timing of drug administration.
SWITCHING FROM LONG-TERM NA ADMINISTRATION TO PEGYLATED INTERFERON
Late-breaking clinical trials suggest that sequential combination therapy with NA and interferon lead to a better chance of HBsAg loss as compared to NA monotherapy. A prospective randomized controlled trial (the OSST study) showed that HBeAg-positive patients who did not achieve HBeAg seroconversion during long-term ETV treatment were randomly assigned to continue ETV monotherapy or switch to pegylated interferon therapy for 48 weeks. As compared to continuous ETV monotherapy, switching to pegylated interferon resulted in significantly increased rates of HBeAg seroconversion and HBsAg loss [53] . The OSST follow-up study showed that rates of HBeAg seroconversion increased from 17.7% at the end of treatment to 38.7% after 1 year of follow-up and that HBsAg seroclearance was durable in 85.7% of patients [54] . The results were in line with those of previous studies of patients receiving sequential combination therapy with NAs and interferon, except that these studies were conducted on a limited number of patients [55, 56] . In an exploratory study, one group of patients with chronic hepatitis B involving a high viral load and non-D genotypes received ETV alone for 12 weeks, ETV plus pegylated interferon for 12 weeks, and pegylated interferon alone for 36 weeks, and another group received a standard 48-week course of pegylated interferon [57] . Comparison of the 2 groups revealed that the sequential combination therapy led to significantly higher rates of HBeAg and HBsAg seroconversion. The NEW SWITCH study of HBeAg-positive patients who achieved partial response without HBeAg seroconversion during long-term NA treatment also demonstrated that switching to pegylated interferon was likely to attain a high HBsAg loss rate, with HBsAg loss after treatment for 96 weeks greater than that after 48 weeks [58] . A recent pilot and proof-of-concept study (the Endeavor study) assessed the loss of HBsAg after sequential combination therapy with interferon plus recombinant human interleukin 2 and therapeutic vaccine in patients who achieved HBeAg loss during long-term ETV treatment. The results showed that this combination treatment strategy led to a numerically higher rate of HBsAg loss as compared to interferon or continuous ETV treatment [59] .
Recent studies suggest that quantitation of HBsAg serves as a useful marker for predicting treatment response and making decisions about sequential combination therapy [60] . The OSST study demonstrated that ETV-treated patients who achieved HBeAg loss with a low baseline HBsAg titer (<1500 IU/mL) were recommended to switch to pegylated interferon because they had a good chance of achieving HBeAg seroconversion and HBsAg clearance. Patients with HBsAg titers of <200 IU/ mL at week 12 had the greatest chance of success. However, for those with HBsAg titers of >1500 IU/mL at week 12, discontinuation of pegylated interferon treatment should be considered since they had a minimal chance of achieving serological response [52] . These results are similar to previous findings and results from recent studies, including the Endeavor and NEW SWITCH studies, which demonstrated that the HBsAg level at baseline and during treatment can help predict HBsAg decline or loss during interferon-based combination therapy (Figure 1 ) [58] [59] [60] [61] . On the other hand, the exploratory analyses of predictors associated with response involved only a small number of patients, and thus the results should be interpreted cautiously and warrant further studies before clinical application.
ADDITION OF PEGYLATED INTEFERON TO A STABLE NA REGIMEN
Recently, a new combination therapy approach, involving NA treatment plus add-on pegylated interferon, has been shown to improve response rates. An observational study demonstrated that, among patients with chronic hepatitis B with undetectable viremia, 2 of 12 achieved HBsAg seroconversion after the addition of pegylated interferon to stable oral therapy [62] . A prospective study showed that the addition of pegylated interferon resulted in sustained HBsAg seroclearance and cessation of NA treatment in 6 of 10 HBeAg-negative patients undergoing long-term NA treatment who achieved virologic response [63] .
A recent randomized controlled trial (the ARES study) evaluated the efficacy of 24 weeks of ETV monotherapy followed by an additional 24 weeks of pegylated interferon therapy in HBeAgpositive patients versus that of standard ETV monotherapy. The combination strategy did not increase the rate of response (defined as an HBV DNA load of <200 IU/mL with HBeAg loss at week 48) but led to a higher rate of HBeAg seroconversion, to marked reduction in the HBsAg level, and to a decreased rate of posttreatment relapse, thereby helping facilitate cessation of NA treatment [64] . A randomized trial demonstrated that, compared with pegylated interferon monotherapy, a combination regimen of ETV pretreatment or pegylated interferon plus add-on ETV significantly improved rates of virologic response during treatment but failed to increase sustained response after treatment among treatment-naive HBeAg-positive patients [65] .
Owing to differences in study designs and case-control selection, it is difficult to determine at present the optimal combination therapy to obtain the best treatment outcomes in patients with chronic hepatitis B. Nevertheless, it is conceivable that once suppression of HBV replication has been achieved by NA treatment, the addition of pegylated interferon will be more effective and beneficial. These clinical trials provide new therapeutic concepts, which need further investigation before being introduced into routine clinical practice.
IMMUNE RESTORATION INDUCED BY INTERFERON-BASED COMBINATION THERAPY
The dysfunctional innate and adaptive antiviral immune responses are involved in the immunopathogenesis of chronic HBV infection through mechanisms of virus-host interaction, including the suppression of natural killer (NK) cell activity, the activation of regulatory T cells, and the exhaustion of viral specific cytotoxic lymphocytes. Several studies highlight the critical role of the immune response in the resolution of HBV Baseline Evaluation Baseline: NAs >1y, HBV DNA load < 1000 copies/mL, HBeAg level < PEIU/mL Treatment stopped (98% received NVP); HBsAg loss, 1.7% (1/58) [53] HBsAg loss, 26.5% (18/68) [58] HBsAg loss, 25% (3/12) [59] HBsAg level >1500 IU/mL HBsAg level between >200 and <1500 IU/mL infection [66] [67] [68] . Further investigations on the mechanism involved in the restoration of impaired immune function by interferon-based combination therapy may help guide future clinical trial design.
Accumulating data indicate that NA and pegylated interferon influence the host immune response in different ways. Pegylated interferon predominantly modulates the innate immune response, especially NK cell activity. Micco et al evaluated the effects of pegylated interferon on NK cells and CD8 + T cells. They found that pegylated interferon induced the production of interleukin 15 and promoted the activation, expansion, and antiviral activity of CD56 bright NK cells, with increased expression of interferon γ and TRAIL. Yet pegylated interferon also led to sustained depletion of effector CD8 + T cells and showed a limited capacity to restore the function of HBV-specific T cell [69] . Several studies suggested that pegylated interferon therapy could restore the reduced expression of Toll-like receptor 3 (TLR3) and TLR9 on peripheral CD14 + monocytes in patients with chronic hepatitis B [70, 71] . However, a contrasting effect of pegylated interferon was observed on T cells. Consistent with the data obtained by Micco et al, Penna et al reported that pegylated interferon did not enhance early circulating HBVspecific T-cell responses among HBeAg-negative patients with chronic hepatitis B [72] , indicating different effects of pegylated interferon on innate and adaptive antiviral immune responses. Potent NA treatment cannot restore the antiviral capacity of NK cells [73] . However, the impact of NA on T cells differs from that of interferon. Some studies have demonstrated that the impaired T-cell function could be restored transiently and partially by NA treatment. A recent study revealed that, in patients achieving viral suppression due to long-term NA treatment, the dysfunctional HBV-specific T cells had a significant functional recovery following in vitro culture [18] .
More evidence suggests that immune restoration is a crucial step toward functional cure of chronic hepatitis B. The mechanistic rationale for using a combination of 2 drugs to treat chronic HBV infection involves the observations that NAs and pegylated interferon have differential effects on innate and adaptive immunity and that suppression of HBV replication by NAs prolongs the innate immune response to pegylated interferon [74] [75] [76] . A recent study evaluating the function of HBV-specific T cells from patients with a high HBV load demonstrated that, in patients who achieved HBsAg clearance, ADV and pegylated interferon combination therapy resulted in partial restoration of HBV-specific T cells [75] . Suppression of HBV replication by prior long-term NA treatment may contribute to partial functional restoration of the adaptive immune response, and subsequent use of an immunomodulator such as pegylated interferon can further boost the innate immune system and thus increase the chance of success of antiviral therapy. According to this scenario, it is conceivable that sequential therapy with pegylated interferon after long-term NA treatment may lead to a higher probability of HBsAg seroclearance. In line with this theory, the OSST study demonstrated that successful serologic response to sequential pegylated interferon therapy was associated with significant restoration of impaired immune responses before week 24, including higher proportions of TLR2-expressing CD14 + monocytes, increased proportions of NKG2C-expressing NK cells, and decreased proportions and diminished inhibitory function of regulatory T cells [77] . These results indicate that the recovery and activation of the immune system during the early phase of combination treatment will help patients with chronic hepatitis B reach the treatment goal. However, comprehensive analyses of the innate and adaptive immune system, in parallel with large prospective clinical trials, are needed to further understand the factors associated with outcomes of combination therapy.
CONCLUSIONS
The obstacles in eliminating cccDNA and breaking the immune tolerance constitute the major difficulties for a cure of HBV infection. Complete HBV control depends not only on the sustained suppression of HBV replication, but also on the induction of an effective antiviral immune response [78] . Currently, several strategies, including antivirals targeting various stages of the HBV life cycle (eg, HBV entry, viral replication, HBV cccDNA production, and viral protein expression), as well as immunotherapeutic agents, are being explored in experimental models or have reached clinical testing, which may have the potential to complement interferon-based therapy.
Combination treatment with NA and pegylated interferon is an encouraging strategy to optimize treatment efficacy and improve the chance of clinical cure. Although it is difficult to determine at present which combination therapy strategy is the most beneficial, it is conceivable that sequential combination therapy with NA and interferon may achieve better outcome than either therapy given alone, since NA reduces the viral load and subsequently enhances the immune response to interferon [79] . With novel therapeutic approaches approved for clinical use in the near future, we assume that combination of these new strategies with currently available antivirals will synergistically enhance the host immune responses and eliminate cccDNA, ultimately leading to a complete cure of HBV infection. Recently, several large prospective randomized trials (eg, the Anchor study) investigating the efficacy of sequential combination treatment with NA, interferon, and immunotherapeutic agents (eg, granulocyte macrophage colony-stimulating factor and therapeutic vaccine) get underway to confirm this hypothesis. 
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